
## Marcelo De Carvalho Bittencourt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3687657/publications.pdf Version: 2024-02-01



MARCELO DE CARVALHO

#	Article	IF	CITATIONS
1	Post-SARS-CoV-2 vaccination specific antibody decrease : Let's get the half-full glass perspective. Journal of Infection, 2022, 84, 94-118.	3.3	2
2	Relationship between clinical remission of perianal fistulas in Crohn's disease and serum adalimumab concentrations: A multi-center cross-sectional study. World Journal of Gastroenterology, 2022, 28, 961-972.	3.3	3
3	Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases. European Journal of Internal Medicine, 2021, 91, 45-52.	2.2	10
4	ACPA-positive versus ACPA-negative rheumatoid arthritis: two distinct erosive disease entities on radiography and ultrasonography. Rheumatology International, 2020, 40, 615-624.	3.0	21
5	A Longitudinal Study of Immune Cells in Severe COVID-19 Patients. Frontiers in Immunology, 2020, 11, 580250.	4.8	53
6	Antiviral and Immunomodulatory Effects of Phytochemicals from Honey against COVID-19: Potential Mechanisms of Action and Future Directions. Molecules, 2020, 25, 5017.	3.8	70
7	Good IgA Bad IgG in SARS-CoV-2 Infection?. Clinical Infectious Diseases, 2020, 71, 897-898.	5.8	23
8	Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer. British Journal of Cancer, 2019, 121, 405-416.	6.4	63
9	Predictors of Flares in Infliximab-treated Children With Inflammatory Bowel Disease. Crohn's & Colitis 360, 2019, 1, .	1.1	2
10	Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis. Journal of Crohn's and Colitis, 2019, 13, 970-975.	1.3	32
11	Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. Alimentary Pharmacology and Therapeutics, 2018, 47, 906-912.	3.7	85
12	Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial. Journal of Hematology and Oncology, 2017, 10, 102.	17.0	39
13	An Early Immediate Early Protein IE-1–Specific T-Cell Polyfunctionality Is Associated With a Better Control of Cytomegalovirus Reactivation in Kidney Transplantation. Kidney International Reports, 2017, 2, 486-492.	0.8	5
14	A rare case of extremely high counts of circulating tumor cells detected in a patient with an oral squamous cell carcinoma. BMC Cancer, 2016, 16, 552.	2.6	9
15	Adenovirus-specific T-cell Subsets in Human Peripheral Blood and After IFN-Î <sup>3</sup> Immunomagnetic Selection. Journal of Immunotherapy, 2016, 39, 27-35.	2.4	6
16	Diagnostic and Prognostic Value of Circulating Tumor Cells in Head and Neck Squamous Cell Carcinoma: a systematic review and meta-analysis. Scientific Reports, 2016, 6, 20210.	3.3	72
17	Interferon-Î <sup>3</sup> Release Assay vs. Tuberculin Skin Test for Tuberculosis Screening in Exposed Healthcare Workers: A Longitudinal Multicenter Comparative Study. Infection Control and Hospital Epidemiology, 2015, 36, 569-574.	1.8	10
18	CellSearch® technology applied to the detection and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal metastasis. Lung Cancer, 2015, 90, 352-357.	2.0	42

Marcelo De Carvalho

#	Article	IF	CITATIONS
19	Combination of <scp>CD</scp> 160 and <scp>CD</scp> 200 as a useful tool for differential diagnosis between chronic lymphocytic leukemia and other mature Bâ€cell neoplasms. International Journal of Laboratory Hematology, 2015, 37, 486-494.	1.3	20
20	Three Weeks of Murine Hindlimb Unloading Induces Shifts from B to T and from Th to Tc Splenic Lymphocytes in Absence of Stress and Differentially Reduces Cell-Specific Mitogenic Responses. PLoS ONE, 2014, 9, e92664.	2.5	75
21	Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigenÂBZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy. Cytotherapy, 2014, 16, 122-134.	0.7	7
22	Case Report: Detection and quantification of tumor cells in peripheral blood and ascitic fluid from a metastatic esophageal cancer patient using the CellSearchî technology. F1000Research, 2014, 3, 12.	1.6	4
23	Detection and quantification of CSF malignant cells by the CellSearch® technology in patients with melanoma leptomeningeal metastasis. Medical Oncology, 2013, 30, 538.	2.5	55
24	Screening for Latent Tuberculosis Infection in Patients with Chronic Inflammatory Arthritis: Discrepancies Between Tuberculin Skin Test and Interferon-Î <sup>3</sup> Release Assay Results. Journal of Rheumatology, 2013, 40, 1986-1993.	2.0	26
25	Value of HIV patients with regular follow-up as In-house Internal Controls of Flow Cytometry Measurement of Lymphocyte Subsets. , 2013, 84, 324-326.		1
26	Differential Effects Of Triggering Via Toll Like Receptors In Stable Or Aggressive Chronic Lymphocytic Leukemia. Blood, 2013, 122, 5296-5296.	1.4	0
27	Follicular Proinflammatory Cytokines and Chemokines as Markers of IVF Success. Clinical and Developmental Immunology, 2012, 2012, 1-10.	3.3	78
28	Active Toll-like receptor-7 triggering of chronic lymphocytic leukemia B-cells by imiquimod. Leukemia and Lymphoma, 2012, 53, 739-742.	1.3	4
29	Combination Biomarkers to Diagnose Sepsis in the Critically III Patient. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 65-71.	5.6	253
30	Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC Clinical Pathology, 2012, 12, 21.	1.8	53
31	Decreased Peripheral Dendritic Cell Numbers in Dengue Virus Infection. Journal of Clinical Immunology, 2012, 32, 161-172.	3.8	28
32	Reduced levels of both circulating CD4+CD25+CD127low/neg and CD4+CD8neg invariant natural killer regulatory T cells in stable heart transplant recipients. Clinical and Experimental Immunology, 2011, 163, 104-112.	2.6	10
33	Long term culture of mesenchymal stem cells in hypoxia promotes a genetic program maintaining their undifferentiated and multipotent status. BMC Cell Biology, 2011, 12, 12.	3.0	205
34	Normal levels of peripheral CD19 <sup>+</sup> CD5 <sup>+</sup> CLLâ€like cells: Toward a defined threshold for CLL followâ€up—A GEILâ€GOELAMS study. Cytometry Part B - Clinical Cytometry, 2011, 80B, 346-353.	1.5	14
35	Mutual benefits of B-ALL and HLDA/HCDM HLDA 9th Barcelona 2010. Immunology Letters, 2011, 134, 145-149.	2.5	6
36	CD49d blockade by natalizumab therapy in patients with multiple sclerosis increases immature B-lymphocytes. Bone Marrow Transplantation, 2011, 46, 1489-1491.	2.4	23

Marcelo De Carvalho

#	Article	IF	CITATIONS
37	Rapid Generation of Full Clinical-Grade Human Antiadenovirus Cytotoxic T Cells for Adoptive Immunotherapy. Journal of Immunotherapy, 2010, 33, 414-424.	2.4	25
38	Standardization of plateletâ€derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. Journal of Thrombosis and Haemostasis, 2010, 8, 2571-2574.	3.8	305
39	Histone deacetylase–mediated transcriptional activation reduces proviral loads in HTLV-1–associated myelopathy/tropical spastic paraparesis patients. Blood, 2007, 110, 3722-3728.	1.4	70
40	Intravenous apoptotic spleen cell infusion induces a TGF-β-dependent regulatory T-cell expansion. Cell Death and Differentiation, 2006, 13, 41-52.	11.2	138
41	Extracellular lysosome-associated membrane protein-1 (LAMP-1) mediates autoimmune disease progression in the NOD model of type 1 diabetes. European Journal of Immunology, 2005, 35, 1501-1509.	2.9	2
42	T-cell flow-cytometry crossmatch and long-term renal graft survival. Clinical Transplantation, 2004, 18, 558-563.	1.6	23
43	Intravenous Infusion of Apoptotic Cells Simultaneously with Allogeneic Hematopoietic Grafts Alters Anti-Donor Humoral Immune Responses. American Journal of Transplantation, 2004, 4, 1361-1365.	4.7	35
44	IL-18 Binding Protein Protects Against Contact Hypersensitivity. Journal of Immunology, 2003, 171, 1164-1171.	0.8	37
45	Influence of Ex Vivo Expansion and Retrovirus-Mediated Gene Transfer on Primary T Lymphocyte Phenotype and Functions. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 929-940.	1.8	26
46	Cell-based therapy approaches using dying cells: from tumour immunotherapy to transplantation tolerance induction. Expert Opinion on Biological Therapy, 2002, 2, 249-263.	3.1	10
47	Exposure to exogenous DNA can modify the sensitivity of the Fas apoptotic pathway. Journal of Gene Medicine, 2002, 4, 14-24.	2.8	7
48	Transfection, but not retroviral transduction, upregulates apoptotic pathways in murine fibroblasts. Transplantation Proceedings, 2001, 33, 268-270.	0.6	0
49	Intravenous injection of apoptotic leukocytes enhances bone marrow engraftment across major histocompatibility barriers. Blood, 2001, 98, 224-230.	1.4	134
50	Flow-PRA® evaluation for antibody screening in patients awaiting kidney transplantation. Transplant Immunology, 2000, 8, 125-128.	1.2	41
51	Flow-PRA evaluation for antibody screening in patients awaiting kidney transplantation. Transplantation Proceedings, 2000, 32, 2745-2746.	0.6	7
52	Anti-class II antibodies in kidney transplant patients. Transplantation Proceedings, 2000, 32, 2748-2749.	0.6	6
53	GANCICLOVIR-SENSITIVE ACUTE GRAFT-VERSUS-HOST DISEASE IN MICE RECEIVING HERPES SIMPLEX VIRUS-THYMIDINE KINASE???EXPRESSING DONOR T CELLS IN A BONE MARROW TRANSPLANTATION SETTING1. Transplantation, 2000, 69, 503-508.	1.0	29
54	Transplantation of Anergic Histoincompatible Bone Marrow Cells. New England Journal of Medicine, 1999, 341, 1081-1082.	27.0	4

Marcelo De Carvalho

#	Article	IF	CITATIONS
55	Differential effects of cyclosporin A on the alloreactivity of fresh and ex vivo-expanded T lymphocytes. Bone Marrow Transplantation, 1998, 22, 1097-1102.	2.4	15
56	T–cell flow–cytometry cross–match: influence in renal transplantation. Transplantation Proceedings, 1998, 30, 2800-2801.	0.6	3
57	Impaired renal graft survival after a positive B-cell flow-cytometry crossmatch. Nephrology Dialysis Transplantation, 1998, 13, 2059-2064.	0.7	34
58	IN VIVO ALLOREACTIVE POTENTIAL OF EX VIVO-EXPANDED PRIMARY T LYMPHOCYTES1. Transplantation, 1998, 65, 1365-1370.	1.0	51
59	Fortuitous detection of uniparental isodisomy of chromosome 6 Journal of Medical Genetics, 1997, 34, 77-78.	3.2	18
60	B-cell flow-cytometry crossmatch: Influence in renal transplantation. Transplantation Proceedings, 1997, 29, 1456-1457.	0.6	5